Tags

Type your tag names separated by a space and hit enter

Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
Infection. 2004 Jun; 32(3):149-52.I

Abstract

BACKGROUND

This study was designed to assess the early antibody kinetics after a priming dose, and the extent of the antibody increase after a booster dose of an inactivated virosomal hepatitis A virus (HAV) vaccine (Epaxal).

PATIENTS AND METHODS

This was an open, uncontrolled study in 30 healthy subjects. The vaccine was injected intramuscularly on day 1 and month 12. Serum antibody titers were measured by ELISA on day 1 (pre dose) and at various time points thereafter until month 12 (pre-booster dose). After the booster dose, antibody titers were measured at various intervals until month 24. Neutralizing antibody titers were measured in 12 subjects a number of times during the 1st month by an antibody neutralization assay. Titers > or = 10 mIU/ml were considered seroprotective.

RESULTS

ELISA antibody titers showed a rapid increase post vaccination. By day 15, 96% of subjects were seroprotected, which increased to 100% by day 22 (n = 27 evaluable subjects, aged 18-43 years; 13 male, 14 female). All subjects achieved seroprotective HAV-neutralizing antibody titers by day 11 (n = 12). The booster vaccination at month 12 resulted in a strong response in all subjects, with a sustained anti-HAV antibody titer (1,155 mIU/ml) at month 24. Both the priming and booster doses were well tolerated.

CONCLUSION

Primary vaccination with this virosomal HAV vaccine is well tolerated and induces a rapid HAV-neutralizing antibody response resulting in seroprotection in all subjects within 10 days. In addition, the booster vaccination results in prolonged seroprotective antibody levels.

Authors+Show Affiliations

Dept. of Specific Prophylaxis and Tropical Medicine, Institute of Pathophysiology, University of Vienna, Impfzentrum Nord, Austria. f.ambrosch@impfzentrum.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15188074

Citation

Ambrosch, F, et al. "Rapid Antibody Response After Vaccination With a Virosomal Hepatitis a Vaccine." Infection, vol. 32, no. 3, 2004, pp. 149-52.
Ambrosch F, Finkel B, Herzog C, et al. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection. 2004;32(3):149-52.
Ambrosch, F., Finkel, B., Herzog, C., Koren, A., & Kollaritsch, H. (2004). Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection, 32(3), 149-52.
Ambrosch F, et al. Rapid Antibody Response After Vaccination With a Virosomal Hepatitis a Vaccine. Infection. 2004;32(3):149-52. PubMed PMID: 15188074.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. AU - Ambrosch,F, AU - Finkel,B, AU - Herzog,C, AU - Koren,A, AU - Kollaritsch,H, PY - 2003/09/18/received PY - 2004/01/13/accepted PY - 2004/6/10/pubmed PY - 2004/8/13/medline PY - 2004/6/10/entrez SP - 149 EP - 52 JF - Infection JO - Infection VL - 32 IS - 3 N2 - BACKGROUND: This study was designed to assess the early antibody kinetics after a priming dose, and the extent of the antibody increase after a booster dose of an inactivated virosomal hepatitis A virus (HAV) vaccine (Epaxal). PATIENTS AND METHODS: This was an open, uncontrolled study in 30 healthy subjects. The vaccine was injected intramuscularly on day 1 and month 12. Serum antibody titers were measured by ELISA on day 1 (pre dose) and at various time points thereafter until month 12 (pre-booster dose). After the booster dose, antibody titers were measured at various intervals until month 24. Neutralizing antibody titers were measured in 12 subjects a number of times during the 1st month by an antibody neutralization assay. Titers > or = 10 mIU/ml were considered seroprotective. RESULTS: ELISA antibody titers showed a rapid increase post vaccination. By day 15, 96% of subjects were seroprotected, which increased to 100% by day 22 (n = 27 evaluable subjects, aged 18-43 years; 13 male, 14 female). All subjects achieved seroprotective HAV-neutralizing antibody titers by day 11 (n = 12). The booster vaccination at month 12 resulted in a strong response in all subjects, with a sustained anti-HAV antibody titer (1,155 mIU/ml) at month 24. Both the priming and booster doses were well tolerated. CONCLUSION: Primary vaccination with this virosomal HAV vaccine is well tolerated and induces a rapid HAV-neutralizing antibody response resulting in seroprotection in all subjects within 10 days. In addition, the booster vaccination results in prolonged seroprotective antibody levels. SN - 0300-8126 UR - https://www.unboundmedicine.com/medline/citation/15188074/Rapid_antibody_response_after_vaccination_with_a_virosomal_hepatitis_a_vaccine_ L2 - https://doi.org/10.1007/s15010-004-3147-4 DB - PRIME DP - Unbound Medicine ER -